Tagged with clinical research

France France is the third most significant clinical research destination in Europe, participating in 50 percent of the trials initiated across the continent. While favourable government policies and unique strengths such as the National Health Data System contribute to France’s competitiveness, obstacles to further growth remain. In conversation with PharmaBoardroom, Hubert…

France Hubert Mechin, president of AFCROs, the association that groups clinical research organisations in France, details the organisation’s efforts to help its members stay abreast of changes in the European regulatory environment and its creation of a clinical research code of conduct. He discusses France’s competitive edge in clinical trials based…

Turkey Becoming the clinical trials country leader in the region has been set as a primary goal for Turkey’s pharma industry to achieve global competitiveness. The government’s strategy is to increase its share of global clinical studies both in numbers and investment. Today, the country occupies the 26th position with 529…

Turkey Dr Hamdi Akan, head of Turkey’s Clinical Research Association, dives into the country’s opportunities and barriers to become a clinical trials hub, including the world-class infrastructure and the need for a revision of the good clinical practice guidelines. Moreover, he explains why TITCK becoming an International Council for Harmonisation (ICH)…

Puerto Rico José F Rodríguez Orengo is the CEO and Chief Scientific Officer at the Fundación de Investigación (FDI) Clinical Trials, Puerto Rico’s main clinical research centre. In this interview, Rodríguez Orengo highlights his priorities of extending the capabilities and also becoming active in the space of public health. He also discusses…

USA Douglas Peddicord, executive director of ACRO, introduces ACRO’s mission, the evolution of the CRO space in the US and globally, and how the latest political developments are affecting the association and its members. Can you begin by introducing ACRO and its mission? “We at ACRO have always focused on advocating…

Mexico According to a recent World Health Organization study, countries must allocate at least six percent of their GDP to research and development to be considered to have a healthy investment in this area. As Mexico currently only invests 1.8 percent of its GDP into R&D, there is clearly still a…

Mexico The CEO of Accelerium Clinical Research, Ciro Garcia speaks about the trends currently impacting Mexico’s clinical research space, while detailing the company’s ambition to pivot from just one full-service research center to the nation’s leading network of clinical research facilities. Could you please introduce yourself to our international audience as…

Mexico Positioning itself as a flexible local CRO with an in-depth knowledge of the Mexican market, iLS Clinical Research CEO, Alejandro Arias, shares his insights on how to be the ideal partner for international expansion. He speaks about the company’s milestones and background, navigating through the challenges of the Mexican CRO…

Mexico Arturo Rodríguez Jacob, CEO at Infinite Clinical Research (ICR) and president of the national association of CROs (ACROM), explains what make Mexico the regional clinical research hub and showcases how ICR is developing clinical studies for allopathic, biotech, medtech, and herbal medicine companies. Only 15 years ago, the Mexican clinical…

Mexico Dr. Marco A. Martinez Rios, General Director of the National Institute of Cardiology in Mexico elaborates on the institution’s rich history in Mexico and its contributions to cardiology through research, teaching and treatment. As the general director of the National Institute of Cardiology, could you introduce yourself to our international…

Pharma Pharmaceuticals Mauritius’s economic stability, genetic diversity, cost competitiveness, and location make it a perfect location for clinical research; a fact the state is now actively promoting. A further vision of the Mauritian government is to transform the island into a medical hub for clinical research. Besides political and economic stability, a number of…